NetScientific PLC NetScientific invests in ProAxsis (7384A)
24 Fevereiro 2014 - 4:00AM
UK Regulatory
TIDMNSCI
RNS Number : 7384A
NetScientific PLC
24 February 2014
24 February 2014
NetScientific plc
("NetScientific" or the "Group")
NetScientific announces investment in ProAxsis
NetScientific plc (AIM:NSCI, 'NetScientific' or 'The Group'),
the biomedical and healthcare technology commercialisation and
investment group, is pleased to announce its investment in ProAxsis
Ltd ('ProAxsis'), a spin-out from Queen's University Belfast, which
was named one of Northern Ireland's most promising companies in
2013. QUBIS (Queen's University Spin Out Vehicle) will remain an
investor alongside NetScientific, who will take a majority stake in
the company.
As a subsidiary company of NetScientific, ProAxsis will continue
to develop a range of novel medical diagnostic tests to enable
routine monitoring of patients with Cystic Fibrosis and other
chronic respiratory conditions such as Chronic Obstructive
Pulmonary Disease (COPD) either in the clinic or at home.
The technology incorporates the use of ProAxsis's patented
'Protease-Tags' a range of unique molecules, which have the
capacity to rapidly and selectively bind active proteases.
Proteases are a large grouping of enzymes that play essential roles
in normal physiological processes essential for maintaining health.
However, when the normally exquisite control of their action is
lost, proteases can be key triggers or amplifiers of many important
human diseases such as cancer, stroke, cystic fibrosis (CF) and
COPD.
Despite being considered important therapeutic targets and
recognised as biomarkers of disease, there are currently no assay
systems which can measure active proteases outside of academic
research facilities.
The tests being developed by ProAxsis are rapid, easy to use
tests, which trap an active protease within a complex biological
sample and enable an immediate visual readout of its presence.
Sir Richard Sykes, Chairman, NetScientific commented:
"I am delighted we are making progress in all our portfolio
companies and, with the investment in ProAxsis, we have added a
significant new technology to our portfolio."
Professor Brian Walker and Dr Lorraine Martin, co-founders,
ProAxsis added:
"In NetScientific, we have found the ideal partner, affording us
the opportunity to collaborate with a global network for
commercialisation and technical product development."
For further information, please contact:
Liberum Capital (Nomad & Broker) Tel: 020 3100 2000
Chris Bowman / Christopher Britton /
Thomas Bective
Bell Pottinger Tel: 020 7861 3232
Daniel de Belder
Company website:www.netscientific.net
About NetScientific
NetScientific is a healthcare medical technology company that
identifies, develops and commercialises research and technologies
originating from leading universities, teaching hospitals and
research institutes globally, particularly in the United Kingdom
and the United States. The Group is primarily focused on
identifying and developing research and technologies for use in
five chronic disease areas within the healthcare diagnostics
sector: (i) cardiovascular; (ii) liver; (iii) cancer; (iv)
metabolic; and (v) digital health.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCTJMTTMBBTTII
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024